Study of AMG 757 in Participants With Small Cell Lung Cancer (SCLC)
Status:
Not yet recruiting
Trial end date:
2024-08-15
Target enrollment:
Participant gender:
Summary
The main aim of this study is to:
- evaluate safety and efficacy (per Response Evaluation Criteria in Solid Tumors version
1.1 [RECIST 1.1] by investigator) of 2 dose levels of AMG 757 for Part 1 only
- evaluate anti-tumor activity of AMG 757 as determined by objective response rate (ORR)
per RECIST 1.1 by blinded independent central review (BICR) for Part 1 and 2